Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and Innovative Renal Care (IRC), a leading comprehensive kidney care provider in the U.S., today announced the broad availability of Vafseo® (vadadustat) for the treatment of anemia due to chronic kidney disease (CKD) in dialysis patients across all IRC clinics.
Related Questions
How will the nationwide launch of Vafseo® affect Akebia Therapeutics' revenue forecasts and earnings guidance?
What is the expected market share gain for Vafseo® versus existing anemia treatments in the dialysis space, and how might that impact competitor valuations?
Are there any supply chain, pricing, or reimbursement risks associated with scaling Vafseo® across all IRC clinics that could influence the stock's volatility?